82 related articles for article (PubMed ID: 15325701)
1. Molecular genetics and its clinical relevance.
Stilgenbauer S; Döhner H
Hematol Oncol Clin North Am; 2004 Aug; 18(4):827-48, viii. PubMed ID: 15325701
[TBL] [Abstract][Full Text] [Related]
2. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
[TBL] [Abstract][Full Text] [Related]
3. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
4. Genotypic prognostic markers.
Stilgenbauer S; Döhner H
Curr Top Microbiol Immunol; 2005; 294():147-64. PubMed ID: 16323431
[TBL] [Abstract][Full Text] [Related]
5. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations and survival in chronic lymphocytic leukemia.
Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
[TBL] [Abstract][Full Text] [Related]
7. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
Zenz T; Döhner H; Stilgenbauer S
Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
[TBL] [Abstract][Full Text] [Related]
8. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.
Tobin G; Thunberg U; Laurell A; Karlsson K; Aleskog A; Willander K; Söderberg O; Merup M; Vilpo J; Hultdin M; Sundström C; Roos G; Rosenquist R
Haematologica; 2005 Apr; 90(4):465-9. PubMed ID: 15820941
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
[TBL] [Abstract][Full Text] [Related]
10. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
[TBL] [Abstract][Full Text] [Related]
11. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
[TBL] [Abstract][Full Text] [Related]
15. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia.
Vasconcelos Y; Davi F; Levy V; Oppezzo P; Magnac C; Michel A; Yamamoto M; Pritsch O; Merle-Béral H; Maloum K; Ajchenbaum-Cymbalista F; Dighiero G
J Clin Oncol; 2003 Nov; 21(21):3928-32. PubMed ID: 14581416
[TBL] [Abstract][Full Text] [Related]
16. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
[TBL] [Abstract][Full Text] [Related]
17. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
18. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
[TBL] [Abstract][Full Text] [Related]
19. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
20. Frequency of 5'IGH deletions in B-cell chronic lymphocytic leukemia.
Quintero-Rivera F; Nooraie F; Rao PN
Cancer Genet Cytogenet; 2009 Apr; 190(1):33-9. PubMed ID: 19264231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
